SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Pompéia, S.
Right arrow Articles by Bueno, O. F. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pompéia, S.
Right arrow Articles by Bueno, O. F. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Lorazepam induces an atypical dissociation of visual and auditory event-related potentials

S. Pompéia

Departamento de Psicobiologia, UNIFESP, Brazil

G. M. Manzano

Setor de Neurofisiologia Clínica, Departamento de Neurologia, UNIFESP, São Paulo, Brazil

J. C. F. Galduróz

S. Tufik

Departamento de Psicobiologia, UNIFESP, Brazil

O. F. A. Bueno

Departamento Psicobiologia, UNIFESP R. Napoleão de Barros, 925 CEP 04024-002 São Paulo Brazil ofabueno{at}psicobio.epm.br

Lorazepam has been reported to atypically disrupt visual processing compared to other benzodiazepines (BZs), but it is not known to what extent this effect extends to impairment in other modalities. Our objective was to compare the effects of lorazepam with those of flunitrazepam, a BZ with standard effects, on visual and auditory event-related potentials (ERPs) using the same paradigm. The study followed a placebocontrolled, double-blind, parallel group-design and involved single oral doses of lorazepam (2.0 mg), flunitrazepam (1.2 mg) and placebo. Thirty-six young, healthy subjects completed a test battery before and after treatment including classic behavioural tests, visual and auditory ERPs. Both drugs led to comparable alterations on behavioural tests and double-dissociations were found, indicating that the doses used were equipotent: lorazepam was more deleterious than flunitrazepam and placebo in fragmented shape identification, while simple reaction times were prolonged for flunitrazepam in comparison to lorazepam and placebo. Effects on P3 latencies were also distinct: alterations in both modalities for flunitrazepam were equivalent and greater than placebo's. In contrast, lorazepam at the frontal and central electrode sites led to greater changes in visual than in auditory latency, and also to longer visual latencies than flunitrazepam and placebo, but lorazepam's auditory latency effects were only different to placebo's at the parietal electrode site. Peripheral visual changes were not responsible for these effects. Differences in the impairment profile between equipotent doses of lorazepam and flunitrazepam suggests that lorazepam induces atypical central visual processing changes.

Key Words: benzodiazepines • event-related potentials • ERP • flunitrazepam • lorazepam • P3 • P100 • vision

Journal of Psychopharmacology, Vol. 17, No. 1, 31-40 (2003)
DOI: 10.1177/0269881103017001690


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J. Physiol.Home page
S Pompeia, G. Manzano, T. S, and O. Bueno
What makes lorazepam different from other benzodiazepines?
J. Physiol., December 1, 2005; 569(2): 709 - 709.
[Full Text] [PDF]


Home page
J. Physiol.Home page
V. Di Lazzaro, F. Pilato, M. Dileone, P. A. Tonali, and U. Ziemann
Reply from Vincenzo Di Lazzaro, Fabio Pilato, Michele Dileone, Pietro A. Tonali and Ulf Ziemann
J. Physiol., December 1, 2005; 569(2): 710 - 710.
[Full Text] [PDF]



Advertisement